Matthew Vincent Dolan is VP at DEXCOM INC (DXCM). They have made 5 open-market trades across 1 company since 2022, most recently 2025-01-29.
CIK 0001914994
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 5 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| DXCM | 42,044 | $3.7M |
Shares reported on the most recent Form 4, priced at the 2025-01-30 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| DXCM | SELL | 2025-01-29 | 2025-01-30 | $86.91 | $206K | -0.6% | -1.0% | -17.8% |
| DXCM | SELL · 10b5-1 | 2024-05-15 | 2024-05-16 | $126.58 | $613K | -3.1% | -11.5% | -46.8% |
| DXCM | SELL · 10b5-1 | 2024-04-15 | 2024-04-16 | $137.81 | $548K | -8.6% | -3.1% | -16.9% |
| DXCM | SELL · 10b5-1 | 2024-03-15 | 2024-03-19 | $130.20 | $1.1M | +2.3% | -0.4% | -13.6% |
| DXCM | SELL | 2024-03-12 | 2024-03-14 | $134.41 | $1.8M | +6.9% | +2.8% | -10.5% |
| DXCM | SELL · 10b5-1 | 2023-09-01 | 2023-09-01 | $102.32 | $6K | -0.4% | -7.2% | +13.3% |
| DXCM | SELL | 2023-03-16 | 2023-03-17 | $115.00 | $265K | +0.0% | +4.1% | +14.9% |
| DXCM | SELL | 2023-03-13 | 2023-03-14 | $106.27 | $1.3M | +1.8% | +3.7% | +13.2% |
| DXCM | SELL · 10b5-1 | 2023-03-06 | 2023-03-06 | $114.40 | $26K | +1.2% | -0.4% | +10.1% |
| DXCM | SELL · 10b5-1 | 2022-09-01 | 2022-09-06 | $81.63 | $408 | +9.1% | +15.3% | +41.2% |
| DXCM | SELL | 2022-03-15 | 2022-03-17 | $420.79 | $1.3M | +13.2% | +5.6% | -37.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.